|About||Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
|How we share on the AMR Register||To obtain Paratek’s AMR surveillance data for analysis, researchers should use the AMR Register platform to submit a request. The anonymized data will then be made available to the researcher to download. Data for ongoing surveillance programs will be updated annually.|
|Programs Listed for Sharing||Paratek’s AMR surveillance data available on the AMR Register:
• KEYSTONE – Omadacycline
|What information will be provided||Where available, the following data and information is provided for each dataset:
🗹 Raw dataset. This is the dataset containing the anonymized isolate level data collected during the study. The dataset can be downloaded.
🗹 Program description. Information about how the data were collected are provided on the program pages.
🗹 Links to Publications. Links to journal publications based on the data collected are provided on the program pages.
|Questions or enquiries||Please send any questions or enquiries to firstname.lastname@example.org|
|Paratek’s Register or Website||http://paratek-keystone.com|